Immunotherapy reduces CD40L expression and modifies cytokine production in the CD4 cells of pollen allergy patients

Journal of Investigational Allergology and Clinical Immunology

Volumn 24, Issue 2, 2014, Pages 98-105

  Ardanaz, José Miguel Urra ^a   Carrasco, P ^a   Feo Brito, F ^a   De La Roca, F ^a   Guerra, F ^b   Cabrera, C M ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

CD40 L; Cytokines; Foxp3; Immunotherapy; Pollen allergy

Indexed keywords

ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BREFELDIN A; CD40 LIGAND; CD63 ANTIGEN; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; IONOMYCIN; PHORBOL 12 ACETATE 13 MYRISTATE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MALE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; POLLEN ALLERGY; PRICK TEST; PROTEIN EXPRESSION; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT PLANNING;

ADOLESCENT; ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CHILD; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; RHINITIS, ALLERGIC, SEASONAL;

EID: 84901937015     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Kay AB. Allergy and allergic diseases. N Engl J Med. 2001;344:30-7.
2. Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Pagé N, Olivenstein R, Elias J, Chakir J. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol. 2001;108:430-8.
3. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A. 1992;89:6550-4.
4. Poulsen LK, Hummelshoj L. Triggers of IgE class switching and allergy development. Ann Med. 2007;39:440-56.
5. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, Thunberg S, Deniz G, Valenta R, Fiebig H, Kegel C, Disch R, Schmidt-Weber CB, Blaser K, Akdis CA. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med. 2004;199:1567-75.
6. Shevach EM. Mechanisms of Foxp3+ T Regulatory Cell-Mediated suppression. Immunity. 2009;30:636-45.
7. Gri G, Piconese S, Frossi B, Manfroi V, Merluzzi S, Tripodo C, Viola A, Odom S, Rivera J, Colombo MP, Pucillo CE. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity. 2008;29:771-81.
8. Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, Arbery J, Carr VA, Robinson DS. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet. 2004;363:608-15.
9. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006:6;761-71.
10. Akdis M, Akdis CA. Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov. 2009;8:645-60.
11. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057-61.
12. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD41CD251 regulatory T cells. Nat Immunol. 2003;4:330-6.
13. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515-48.
14. D'Amato G, Gentili M, Russo M, Mistrello G, Saggese M, Liccardi G, Falagiani P. Detection of Parietaria judaica airborne allergenic activity: comparison between immunochemical and morphological methods including clinical evaluation. Clin Exp Allergy. 1994;24:566-74.
15. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, Kay AB, Hamid QA. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cell expressing messenger RNA for interferon gamma. J Allergy Clin Immunol. 1996;97:1356-65.
16. James LK, Durham SR. Update on mechanisms of allergen injection immunotherapy. Clin Exp Allergy. 2008;38:1074-88.
17. Mobs C, Slotosh C, Loffler H, Pfutzner W, Hertl M. Cellular and humoral mechanisms of immune tolerance in immediate-type allergy induced by specific immunotherapy. Int Arch Allergy Immunol. 2008;147:171-8.
18. Akdis CA, Akdis M. Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol. 2009;123:735-46.
19. Pilette C, Nouri-Aria KT, Jacobson MR, Wilcock LK, Detry B, Walker SM, Francis JN, Durham SR. Grass pollen immunotherapy induces an allergen specific IgA2 antibody response with mucosal TGF-beta expression. J Immunol. 2007;178:4658-66.
20. Ajduk J, Marinic I, Aberle N, Rabatic S, Gagro A. Effect of house dust mite immunotherapy on transforming growth factor beta 1-producing T cells in asthmatic children. Ann Allergy Asthma Immunol. 2008;100:314-22.
21. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389:737-42.
22. Wu K, Bi Y, Sun K, Wang C. IL-10-producing type 1 regulatory T cells and allergy. Cell Mol Immunol. 2007;4:269-75.
23. Fujio K, Okamura T, Yamamoto K. The Family of IL-10-secreting CD4+ T cells. Adv Immunol. 2010;105:99-130.
24. Tai X, Van Laethem F, Pobezinsky L, Guinter T, Sharrow SO, Adams A, Granger L, Kruhlak M, Lindsten T, Thompson CB, Feigenbaum L, Singer A. Basis of CTLA-4 function in regulatory and conventional CD4+ T cells. Blood. 2012;119:5155-63.
25. Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-β: the role of T regulatory cells. Immunology. 2006;117:433-42.
26. Muller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F, Blaser K. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998;101:747-54.
27. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, Akdis CA. IL-10 and TGF-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. 2003;33:1205-14.
28. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, Kay AB, Hamid QA. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cell expressing messenger RNA for interferon gamma. J Allergy Clin Immunol. 1996;97:1356-65.
29. Plewako H, Wosinska K, Arvidsson M, Bjorkander J, Hakansson L, Rak S. Production of interleukin-12 by monocytes and interferon-γ by natural killer cells in allergic patients during rush immunotherapy. Ann Allergy Asthma Immunol. 2006;97:464-8.
30. Poulsen LK, Hummelshoj L. Triggers of IgE class switching and allergy development. Ann Med. 2007;39:440-56.
31. Loubaki L, Semlali A, Boisvert M, Jacques E, Plante S, Aoudjit F, Mourad W, Chakir J. Crosstalk between T cells and bronchial fibroblasts obtained from asthmatic subjects involves CD40L/ alpha 5 beta 1 interaction. Mol Immunol. 2010;47:2112-8.
32. Suzuki M, Zheng X, Zhang X, Ichim TE, Sun H, Kubo N, Beduhn M, Shunnar A, Garcia B, Min WP. Inhibition of allergic responses by CD40 gene silencing. Allergy. 2009;64:387-97.
33. Linhart B, Bigenzahn S, Hartl A, Lupinek C, Thalhamer J, Valenta R, Wekerle T. Costimulation blockade inhibits allergic sensitization but does not affect established allergy in a murine model of grass pollen allergy. J Immunol. 2007;178:3924-31.
34. Vogel I, Verbinnen B, Maes W, Boon L, Van Gool SW, Ceuppens JL. Foxp3(+) regulatory T cells are activated in spite of B7-CD28 and CD40-CD40L blockade. Eur J Immunol. 2013;43:1013-23.
35. Ballantyne J, Henry DL, Muller JR, Briere F, Snapper CM, Kehry M, Marcu KB. Efficient recombination of a switch substrate retrovector in CD40-activated B lymphocytes: implications for the control of CH gene switch recombination. J Immunol. 1998;161:1336-47.
36. Campbell JD, Buchmann P, Kesting S, Cunningham CR, Coffman RL, Hessel EM. Allergen-specific T cell responses to immunotherapy monitored by CD154 and intracellular cytokine expression. Clin Exp Allergy. 2010;40:1025-35.
37. Bonvalet M, Wambre E, Moussu H, Horiot S, Kwok WW, Louise A, Ebo D, Hoarau C, Van Overtvelt L, Baron-Bodo V, Moingeon P. Comparison between major histocompatibility complex class II tetramer staining and surface expression of activation markers for the detection of allergen-specific CD41 T cells. Clin Exp Allergy. 2011:41:821-9.
38. Francis JN, James LK, Paraskevopoulos G, Wong C, Calderon MA, Durham SR, Till SJ. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J. Allergy Clin. Immunol. 2008; 121:1120-5.
39. Urra JM, Feo Brito F, Carrasco P, De la Roca F, Zamorano J. Allergen-stimulation induces the simultaneously production of TH2 and regulatory cytokines in T cells from patients with pollen allergy. J Invest Allergol Clin Immunol. 2013;23;55-6.
40. SEIAC. Sociedad Española de Alergología e Inmunología Clínica; Comité de Aerobiología; Accessed August 21 2012. Available at http://www.polenes.com/index.html.